How to Handle Non-Proportional Hazards in Clinical Trial Survival Analysis

Survival analysis is a cornerstone of clinical trials, particularly in therapeutic areas like oncology, cardiology, and immunology. A common assumption in survival analysis—especially when using the Cox proportional hazards model—is that the hazard ratio remains constant over time. But what happens when this assumption doesn’t hold? In real-world trials, non-proportional hazards (NPH) are more common than we expect.

This guide provides a practical tutorial for identifying and managing non-proportional hazards in survival data. We’ll explore statistical tests, visual diagnostics, and alternative modeling techniques, including restricted mean survival time (RMST), stratified Cox models, and time-varying covariates. Proper handling of NPH is essential for robust conclusions and regulatory compliance as required by agencies like EMA.

Understanding the Proportional Hazards Assumption

The Cox proportional hazards model assumes that the ratio of hazard functions between treatment groups is constant over time. This implies that survival curves should not cross and that the treatment effect is consistent throughout follow-up.

Violation of this assumption may occur due to:

• Delayed treatment effects (e.g., immunotherapy)
• Treatment waning over time
• Crossing survival curves
• Time-dependent prognostic factors

Ignoring NPH can lead to biased hazard ratios, misleading p-values, and incorrect trial conclusions, affecting decisions around GMP compliance and product registration.

How to Detect Non-Proportional Hazards

1. Visual Inspection of Kaplan-Meier Curves

• Check for crossing survival curves
• Assess whether the distance between curves varies over time
• Review number-at-risk tables for possible shifts in population composition

2. Schoenfeld Residuals Test

• Formal test to evaluate time-dependency of covariates
• Significant p-value (< 0.05) indicates violation of PH assumption
• Implemented in R via cox.zph() function

3. Log(-log) Survival Plots

• Parallel curves indicate proportionality
• Non-parallel or intersecting curves suggest NPH

Always include diagnostics in your biostatistical analysis plan and Pharma SOPs for trial data modeling.

Methods to Address Non-Proportional Hazards

1. Time-Dependent Cox Regression

• Allows hazard ratios to change over time
• Models treatment effect as a function of time (e.g., include an interaction term: treatment × time)
• Requires segmented time intervals or continuous time-based functions

Example (R syntax):

coxph(Surv(time, status) ~ treatment + tt(treatment), tt = function(x, t, ...) x * log(t))

2. Stratified Cox Models

• Accounts for non-proportionality by stratifying on variables that violate the PH assumption
• Hazard functions vary across strata, but covariates are assumed to act proportionally within each stratum

Best used when the assumption is violated for specific covariates but holds for others.

3. Weighted Log-Rank Tests

• Use different weights across time to emphasize early or late differences
• Common weights: Fleming-Harrington, Tarone-Ware
• Improves sensitivity when treatment effect varies over follow-up

4. Restricted Mean Survival Time (RMST)

• Estimates the average time until event up to a specific time point
• Does not rely on proportional hazards assumption
• Useful for regulatory submissions and benefit-risk evaluations

Regulatory bodies increasingly accept RMST as a complementary endpoint, especially when Kaplan-Meier curves cross significantly.

Practical Example: Delayed Effect in Immuno-Oncology

In a lung cancer trial comparing an immune checkpoint inhibitor to chemotherapy, survival curves crossed at 3 months. Early deaths in the treatment arm created an initial disadvantage, but long-term survivors diverged favorably after 6 months. Standard Cox analysis underestimated the benefit (HR = 0.88, p = 0.12), while RMST and weighted log-rank test showed statistically significant improvements over the control arm.

This case highlights the importance of assessing multiple methods when hazards are not proportional—particularly in adaptive or event-driven studies common in immunotherapy trials.

When to Use Each Method

Regulatory Perspectives

Agencies such as the CDSCO and USFDA require a clear justification of statistical methods, especially when assumptions are violated. Use of non-standard methods must be pre-specified in the Statistical Analysis Plan (SAP), and explained in detail in the Clinical Study Report (CSR).

Include visual diagnostics, alternative estimates like RMST, and sensitivity analyses using different methods to provide a comprehensive interpretation. These strategies align with quality expectations described by Stability Studies documentation practices.

Best Practices

1. Test for proportional hazards using graphical and statistical methods
2. Always prespecify methods for handling NPH in the SAP
3. Use multiple methods to triangulate the treatment effect
4. Report time points where treatment effects change
5. Document all modeling decisions per pharma regulatory guidance

Conclusion

Non-proportional hazards are a common and often overlooked issue in clinical trial survival analysis. Detecting and addressing them appropriately ensures the validity of your results and strengthens regulatory submissions. With tools such as time-varying covariates, RMST, and stratified models, clinical researchers can move beyond basic Cox regression and gain a deeper understanding of time-dependent treatment effects. Incorporating these approaches into standard biostatistics practice will enhance the clarity and impact of survival outcomes in clinical research.